Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP process.

Nelson J, Rodriguez S, Finlayson N, Williams J, Carnes A.

Hum Vaccin Immunother. 2013 Oct;9(10):2211-5. doi: 10.4161/hv.25048. Epub 2013 Jul 30.

2.

Comparative efficacy and immunogenicity of replication-defective, recombinant glycoprotein, and DNA vaccines for herpes simplex virus 2 infections in mice and guinea pigs.

Hoshino Y, Dalai SK, Wang K, Pesnicak L, Lau TY, Knipe DM, Cohen JI, Straus SE.

J Virol. 2005 Jan;79(1):410-8. Erratum in: J Virol. 2005 Apr;79(7):4554.

3.

Phase I study of a herpes simplex virus type 2 (HSV-2) DNA vaccine administered to healthy, HSV-2-seronegative adults by a needle-free injection system.

Cattamanchi A, Posavad CM, Wald A, Baine Y, Moses J, Higgins TJ, Ginsberg R, Ciccarelli R, Corey L, Koelle DM.

Clin Vaccine Immunol. 2008 Nov;15(11):1638-43. doi: 10.1128/CVI.00167-08. Epub 2008 Sep 10.

4.

Immunological properties of a DNA plasmid encoding a chimeric protein of herpes simplex virus type 2 glycoprotein B and glycoprotein D.

Domingo C, Gadea I, Pardeiro M, Castilla C, Fernández S, Fernández-Clua MA, De la Cruz Troca JJ, Punzón C, Soriano F, Fresno M, Tabarés E.

Vaccine. 2003 Sep 8;21(25-26):3565-74.

PMID:
12922084
5.

Enhancement of protective humoral immune responses against Herpes simplex virus-2 in DNA-immunized guinea-pigs using protein boosting.

Fotouhi F, Soleimanjahi H, Roostaee MH, Behzadian F.

FEMS Immunol Med Microbiol. 2008 Oct;54(1):18-26. doi: 10.1111/j.1574-695X.2008.00438.x. Epub 2008 Jul 21.

6.
8.
10.

A lentiviral vector-based, herpes simplex virus 1 (HSV-1) glycoprotein B vaccine affords cross-protection against HSV-1 and HSV-2 genital infections.

Chiuppesi F, Vannucci L, De Luca A, Lai M, Matteoli B, Freer G, Manservigi R, Ceccherini-Nelli L, Maggi F, Bendinelli M, Pistello M.

J Virol. 2012 Jun;86(12):6563-74. doi: 10.1128/JVI.00302-12. Epub 2012 Apr 4.

11.

Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs.

Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, Straus SE, Cohen JI.

Vaccine. 2008 Jul 29;26(32):4034-40. doi: 10.1016/j.vaccine.2008.05.022. Epub 2008 Jun 2.

12.

Critical design criteria for minimal antibiotic-free plasmid vectors necessary to combine robust RNA Pol II and Pol III-mediated eukaryotic expression with high bacterial production yields.

Carnes AE, Luke JM, Vincent JM, Anderson S, Schukar A, Hodgson CP, Williams JA.

J Gene Med. 2010 Oct;12(10):818-31. doi: 10.1002/jgm.1499.

13.

Vaxfectin-adjuvanted plasmid DNA vaccine improves protection and immunogenicity in a murine model of genital herpes infection.

Shlapobersky M, Marshak JO, Dong L, Huang ML, Wei Q, Chu A, Rolland A, Sullivan S, Koelle DM.

J Gen Virol. 2012 Jun;93(Pt 6):1305-15. doi: 10.1099/vir.0.040055-0. Epub 2012 Mar 7.

14.

Automated fed-batch fermentation with feed-back controls based on dissolved oxygen (DO) and pH for production of DNA vaccines.

Chen W, Graham C, Ciccarelli RB.

J Ind Microbiol Biotechnol. 1997 Jan;18(1):43-8.

PMID:
9079287
15.

Plasmid fermentation process for DNA immunization applications.

Carnes AE, Williams JA.

Methods Mol Biol. 2014;1143:197-217. doi: 10.1007/978-1-4939-0410-5_13.

PMID:
24715290
16.

Comparison of intramuscular and footpad subcutaneous immunization with DNA vaccine encoding HSV-gD2 in mice.

Jazayeri M, Soleimanjahi H, Fotouhi F, Pakravan N.

Comp Immunol Microbiol Infect Dis. 2009 Sep;32(5):453-61. doi: 10.1016/j.cimid.2008.05.002. Epub 2008 Jun 20.

PMID:
18571235
17.
18.

An ocular mucosal administration of nanoparticles containing DNA vaccine pRSC-gD-IL-21 confers protection against mucosal challenge with herpes simplex virus type 1 in mice.

Hu K, Dou J, Yu F, He X, Yuan X, Wang Y, Liu C, Gu N.

Vaccine. 2011 Feb 4;29(7):1455-62. doi: 10.1016/j.vaccine.2010.12.031. Epub 2010 Dec 24.

PMID:
21185849
19.

Use of Staby(®) technology for development and production of DNA vaccines free of antibiotic resistance gene.

Reschner A, Scohy S, Vandermeulen G, Daukandt M, Jacques C, Michel B, Nauwynck H, Xhonneux F, Préat V, Vanderplasschen A, Szpirer C.

Hum Vaccin Immunother. 2013 Oct;9(10):2203-10. doi: 10.4161/hv.25086. Epub 2013 Jun 4.

20.

Herpes simplex virus type 2 vaccines: new ground for optimism?

Aurelian L.

Clin Diagn Lab Immunol. 2004 May;11(3):437-45. Review.

Supplemental Content

Support Center